gdc

Skin Cancer

Immunotherapy a Safe Option in Immunocompromised Patients with Advanced Skin Cancer
ImmunotherapySkin Cancer
Immunotherapy is showing good results in patients with advanced skin cancer, one of the most common types of cancer diagnosed in the United States.
Climate Change Plays Havoc on Weather Patterns, and on Skin Cancer Rates
Skin CancerPatient Stories
Mark Ryan, RN, is not worried about the impact of climate change on the weather, but on skin cancer, which he knows first-hand. A decrease in stratospheric ozone requires stringent environmental regulations to prevent cancer, he says.
Libtayo Approved for Some Patients with Basal-Cell Carcinoma
FDA Approvals, News & UpdatesSkin Cancer
The immunotherapy Libtayo is a new treatment option for advanced or metastatic basal-cell carcinoma, a type of skin cancer. Libtayo was initially approved for a different type of skin cancer.
Tips and Tools for Skin Self-Checks for Early Detection of Skin Cancer
Skin CancerCancer Screening
Dr. Andrew Weinstein, a dermatologist, stresses the importance of monitoring skin changes regularly, giving advice and information regarding skin cancer, the most common cancer in the USA.
Drugs for Skin Cancer/Merkel-Cell Carcinoma
Skin Cancer
Here are the drugs and financial support services available to patients receiving treatment for Skin Cancer/Merkel-Cell Carcinoma.
Caring for My Husband as He Battles Skin Cancer
CaregiversSkin Cancer
Caring for her husband Bill as he deals with skin cancer, Cathie Balthazor shares the importance of being there to listen to your loved one and care for his or her emotional life.
Is It Breast or Skin Cancer? How a Misdiagnosis Shaped My Cancer Journey
ImmunotherapyPatient StoriesSkin Cancer
Chris Andersen learned the value of trusting one’s instincts and asking for a second opinion after receiving a misdiagnosis of breast cancer that was later diagnosed as metastatic skin cancer and she was told she had 1 to 2 years to live. Thanks to a new treatment for skin cancer, she now has no signs of cancer.
Libtayo Extends Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
Skin Cancer
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
Page 1 of 3
Results 1 - 10 of 22

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest